Cited by 188Down syndrome and intellectual disability researchNeurogenesis and neuroplasticity mechanismsGenetics and Neurodevelopmental Disorders

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome

Open access

Bianchi, P., Ciani, E., Guidi, S., Trazzi, S., Felice, D., Grossi, G., Fernandez, M., Giuliani, A., Calza, L., Bartesaghi, R.·2010·Journal of Neuroscience

DOI 10.1523/jneurosci.0534-10.2010PMC PMC6632890

Open this paper in CoChat — free account Open PDF

Abstract

Down syndrome (DS) is a genetic pathology characterized by intellectual disability and brain hypotrophy. Widespread neurogenesis impairment characterizes the fetal and neonatal DS brain, strongly suggesting that this defect may be a major determinant of mental retardation. Our goal was to establish, in a mouse model for DS, whether early pharmacotherapy improves neurogenesis and cognitive behavior. Neonate Ts65Dn mice were treated from postnatal day (P) 3 to P15 with fluoxetine, an antidepressant that inhibits serotonin (5-HT) reuptake and increases proliferation in the adult Ts65Dn mouse (Clark et al., 2006). On P15, they received a BrdU injection and were killed after either 2 h or 1 month. Results showed that P15 Ts65Dn mice had notably defective proliferation in the hippocampal dentate gyrus, subventricular zone, striatum, and neocortex and that proliferation was completely rescued by fluoxetine. In the hippocampus of untreated P15 Ts65Dn mice, we found normal 5-HT levels but a lower expression of 5-HT1A receptors and brain-derived neurotrophic factor (BDNF). In Ts65Dn mice, fluoxetine treatment restored the expression of 5-HT1A receptors and BDNF. One month after cessation of treatment, there were more surviving cells in the dentate gyrus of Ts65Dn mice, more cells with a neuronal phenotype, more proliferating precursors, and more granule cells. These animals were tested for contextual fear conditioning, a hippocampus-dependent memory task, and exhibited a complete recovery of memory performance. Results show that early pharmacotherapy with a drug usable by humans can correct neurogenesis and behavioral impairment in a model for DS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1523/jneurosci.0534-10.2010

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Chromosome 21-derived MicroRNAs Provide an Etiological Basis for Aberrant Protein Expression in Human Down Syndrome Brains
Kuhn, D. E., Nuovo, G. J., Terry, A. V., Martin, M. M., Malana, G. E., Sansom, S. E., Pleister, A. P., Beck, W. D., Head, E., Feldman, D. S., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033407 · Cited by 121
Retracted
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2
Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., & Zoghbi, H. Y. (1999) · Nature Genetics · doi:10.1038/13810 · Cited by 4,990
The Ki-67 protein: From the known and the unknown
Scholzen, T. E., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3 · Cited by 4,707
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning.
Phillips, R. G., & LeDoux, J. E. (1992) · Behavioral Neuroscience · doi:10.1037/0735-7044.106.2.274 · Cited by 3,292
mouse brain in stereotaxic coordinates
Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription
Chahrour, M., Jung, S. Y., Shaw, C., Zhou, X., Wong, S. T. C., Qin, J., & Zoghbi, H. Y. (2008) · Science · doi:10.1126/science.1153252 · Cited by 1,823
Multipotent CNS Stem Cells Are Present in the Adult Mammalian Spinal Cord and Ventricular Neuroaxis
Weiss, S., Dunne, C., Hewson, J., Wohl, C. A., Wheatley, M., Peterson, A. C., & Reynolds, B. A. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-23-07599.1996 · Cited by 1,219

Show all 62 references

Sorted by citations

Down syndrome and the complexity of genome dosage imbalance
Antonarakis, S. E. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.154 · Cited by 314
Down syndrome: the brain in trisomic mode
Dierssen, M. (2012) · Nature reviews. Neuroscience · doi:10.1038/nrn3314 · Cited by 288
Rodent models in Down syndrome research: impact and future opportunities
Hérault, Y., Delabar, J. M., Fisher, E., Tybulewicz, V. L. J., Yu, E. Y., & Brault, V. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.029728 · Cited by 206
Depression, dementia and immune dysregulation
Hayley, S., Hakim, A. M., & Albert, P. R. (2021) · Brain · doi:10.1093/brain/awaa405 · Cited by 186
Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities
Rueda, N., Flórez, J., & Martínez-Cué, C. (2012) · Neural Plasticity · doi:10.1155/2012/584071 · Cited by 171
Activation of the ISR mediates the behavioral and neurophysiological abnormalities in Down syndrome
Zhu, P., Khatiwada, S., Cui, Y., Reineke, L. C., Dooling, S. W., Kim, J., Li, W., Walter, P., & Costa‐Mattioli, M. (2019) · Science · doi:10.1126/science.aaw5185 · Cited by 171
Reducing GABA A α5 Receptor-Mediated Inhibition Rescues Functional and Neuromorphological Deficits in a Mouse Model of Down Syndrome
Martínez‐Cué, C., Martinez, P. M., Rueda, N., Vidal, R., García-Cerro, S., Vidal, V., Corrales, A., Montero, J. A., Pazos, Á., Flórez, J., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1203-12.2013 · Cited by 160
The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome
Contestabile, A., Magara, S., & Cancedda, L. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00054 · Cited by 141
Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling
Fuchs, C., Trazzi, S., Torricella, R., Viggiano, R., De Franceschi, M., Amendola, E., Gross, C., Calzà, L., Bartesaghi, R., & Ciani, E. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.06.006 · Cited by 138
Self-citation
Glutamatergic synapses in neurodevelopmental disorders
Moretto, E., Murru, L., Martano, G., Sassone, J., & Passafaro, M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.09.014 · Cited by 146
A randomized, double-blind, placebo-controlled trial of low-dose sertraline in young children with fragile X syndrome
Greiss Hess, L., Fitzpatrick, S. E., Nguyen, D. V., Chen, Y., Gaul, K. N., Schneider, A., Lemons Chitwood, K., Eldeeb, M. A. A. A., Polussa, J., Hessl, D., et al. (2016) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0000000000000334 · Cited by 122
Timing of therapies for Down syndrome: the sooner, the better
Stagni, F., Giacomini, A., Guidi, S., Ciani, E., & Bartesaghi, R. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00265 · Cited by 128
Self-citation
Neurogenesis impairment: An early developmental defect in Down syndrome
Stagni, F., Giacomini, A., Emili, M., Guidi, S., & Bartesaghi, R. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.07.026 · Cited by 120
Self-citation
Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome
Velázquez, R., Ash, J. A., Powers, B. E., Kelley, C. M., Strawderman, M. S., Luscher, Z. I., Ginsberg, S. D., Mufson, E. J., & Strupp, B. J. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.016 · Cited by 124
Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations
Gardiner, K. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s51476 · Cited by 119
APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome
Trazzi, S., Mitrugno, V. M., Valli, E., Fuchs, C., Rizzi, S., Guidi, S., Perini, G., Bartesaghi, R., & Ciani, E. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr033 · Cited by 114
Self-citation
Synaptic regulation of affective behaviors; role of BDNF
Ninan, I. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.011 · Cited by 114
Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and Neuromorphological alterations found in a mouse model of down syndrome
García-Cerro, S., Martínez, P., Vidal, V., Corrales, A., Flórez, J., Vidal, R., Rueda, N., Arbonés, M. L., & Martínez-Cué, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106572 · Cited by 104
The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: A systematic review and meta-analysis: M oraros et al.
Moraros, J., Nwankwo, C., Patten, S. B., & Mousseau, D. D. (2017) · Depression and Anxiety · doi:10.1002/da.22584 · Cited by 105
The use of mouse models to understand and improve cognitive deficits in Down syndrome
Das, I., & Reeves, R. H. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.007716 · Cited by 103
Down syndrome: Neurobiological alterations and therapeutic targets
Vacca, R. A., Bawari, S., Valenti, D., Tewari, D., Nabavi, S. F., Shirooie, S., Sah, A. N., Volpicella, M., Braidy, N., & Nabavi, S. M. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.01.001 · Cited by 98
Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy
Ubhi, K. K., Inglis, C. A., Mante, M., Patrick, C., Adame, A., Spencer, B. J., Rockenstein, E. M., May, V. E. L., Winkler, J., & Masliah, E. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.008 · Cited by 87
Hippocampal deficits in neurodevelopmental disorders
Li, Y., Shen, M., Stockton, M. E., & Zhao, X. (2018) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2018.10.001 · Cited by 89
Wnt signaling in neuropsychiatric disorders: Ties with adult hippocampal neurogenesis and behavior
Hussaini, S. M. Q., Choi, C., Cho, C. H., Kim, H. J., Jun, H., & Jang, M. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.09.005 · Cited by 88
Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice
Ash, J. A., Velázquez, R., Kelley, C. M., Powers, B. E., Ginsberg, S. D., Mufson, E. J., & Strupp, B. J. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.06.001 · Cited by 88
Prenatal pharmacotherapy rescues brain development in a Down’s syndrome mouse model
Guidi, S., Stagni, F., Bianchi, P., Ciani, E., Giacomini, A., Franceschi, M. D., Moldrich, R. X., Kurniawan, N. D., Mardon, K., Giuliani, A., et al. (2013) · Brain · doi:10.1093/brain/awt340 · Cited by 85
Self-citation
Prospects for Improving Brain Function in Individuals with Down Syndrome
Costa, A. C. S., & Scott-McKean, J. J. (2013) · CNS Drugs · doi:10.1007/s40263-013-0089-3 · Cited by 83
Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome
Stagni, F., Giacomini, A., Emili, M., Trazzi, S., Guidi, S., Sassi, M., Ciani, E., Rimondini, R., & Bartesaghi, R. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.07.031 · Cited by 81
Self-citation
Is it possible to improve neurodevelopmental abnormalities in Down syndrome?
Bartesaghi, R., Guidi, S., & Ciani, E. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.037 · Cited by 77
Self-citation
Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome
Parrini, M., Ghezzi, D., Deidda, G., Medrihan, L., Castroflorio, E., Alberti, M., Baldelli, P., Cancedda, L., & Contestabile, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17201-8 · Cited by 77
Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice
Nakano-Kobayashi, A., Awaya, T., Kii, I., Sumida, Y., Okuno, Y., Yoshida, S., Sumida, T., Inoue, H., Hosoya, T., & Hagiwara, M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704143114 · Cited by 76
Early Pharmacotherapy with Fluoxetine Rescues Dendritic Pathology in the Ts65Dn Mouse Model of D own Syndrome
Guidi, S., Stagni, F., Bianchi, P., Ciani, E., Ragazzi, E., Trazzi, S., Grossi, G., Mangano, C., Calzà, L., & Bartesaghi, R. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00624.x · Cited by 68
Self-citation
Inhibition of GSK3β rescues hippocampal development and learning in a mouse model of CDKL5 disorder
Fuchs, C., Rimondini, R., Viggiano, R., Trazzi, S., Franceschi, M. D., Bartesaghi, R., & Ciani, E. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.06.018 · Cited by 67
Self-citation
Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down Syndrome
Begenisic, T., Baroncelli, L., Sansevero, G., Milanese, M., Bonifacino, T., Bonanno, G., Cioni, G., Maffei, L., & Sale, A. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.11.010 · Cited by 66
A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS
Stagni, F., Giacomini, A., Guidi, S., Emili, M., Uguagliati, B., Salvalai, M. E., Bortolotto, V., Grilli, M., Rimondini, R., & Bartesaghi, R. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.08.018 · Cited by 68
Self-citation
Prenatal treatment of Down syndrome
Guedj, F., Bianchi, D. W., & Delabar, J. M. (2014) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000056 · Cited by 62
Role of Adult Hippocampal Neurogenesis in Cognition in Physiology and Disease: Pharmacological Targets and Biomarkers
Costa, V., Lugert, S., & Jagasia, R. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-16522-6_4 · Cited by 63
Treating enhanced GABAergic inhibition in Down syndrome: Use of GABA α5-selective inverse agonists
Martínez-Cué, C., Delatour, B., & Potier, M.-C. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.12.008 · Cited by 58
Chronic treatment with fluoxetine prevents the return of extinguished auditory-cued conditioned fear
Deschaux, O., Spennato, G., Moreau, J., & Garcia, R. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2134-y · Cited by 57
Environmental Enrichment Rescues Postnatal Neurogenesis Defect in the Male and Female Ts65Dn Mouse Model of Down Syndrome
Chakrabarti, L., Scafidi, J., Gallo, V., & Haydar, T. F. (2011) · Developmental Neuroscience · doi:10.1159/000329423 · Cited by 57
Pharmacological interventions to improve cognition and adaptive functioning in down syndrome: strides to date.
Hart, S. J., Visootsak, J., Tamburri, P., Phuong, P., Baumer, N., Hernandez, M., Skotko, B. G., Ochoa‐Lubinoff, C., Liogier D'Ardhuy, X., Kishnani, P. S., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38465 · Cited by 54
Early Intervention Combined with Targeted Treatment Promotes Cognitive and Behavioral Improvements in Young Children with Fragile X Syndrome
Winarni, T. I., Schneider, A., Borodyanskara, M., & Hagerman, R. J. (2012) · Case Reports in Genetics · doi:10.1155/2012/280813 · Cited by 54
From Abnormal Hippocampal Synaptic Plasticity in Down Syndrome Mouse Models to Cognitive Disability in Down Syndrome
Cramer, N., & Galdzicki, Z. (2012) · Neural Plasticity · doi:10.1155/2012/101542 · Cited by 60
Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice
Stagni, F., Giacomini, A., Guidi, S., Ciani, E., Ragazzi, E., Filonzi, M., IASIO, R. D., Rimondini, R., & Bartesaghi, R. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.12.005 · Cited by 55
Self-citation
Perinatal Supplementation with Omega-3 Polyunsaturated Fatty Acids Improves Sevoflurane-Induced Neurodegeneration and Memory Impairment in Neonatal Rats
Lei, X., Zhang, W., Liu, T., Xiao, H., Liang, W., Xia, W., & Zhang, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070645 · Cited by 53
Luteolin induces hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome
Zhou, W., Miao, Z., Zhang, B., Long, W., Zheng, F., Kong, J., & Yu, B. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.248519 · Cited by 53
Therapeutic approaches in the improvement of cognitive performance in Down syndrome
de la Torre, R., & Dierssen, M. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-54299-1.00001-7 · Cited by 53
Sertraline May Improve Language Developmental Trajectory in Young Children with Fragile X Syndrome: A Retrospective Chart Review
Indah Winarni, T., Chonchaiya, W., Adams, E., Au, J., Mu, Y., Rivera, S. M., Nguyen, D. V., & Hagerman, R. J. (2012) · Autism Research and Treatment · doi:10.1155/2012/104317 · Cited by 52
Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers
Hagerman, R. J. (2014) · Brain Disorders & Therapy · doi:10.4172/2168-975x.1000119 · Cited by 53
Chronic melatonin treatment rescues electrophysiological and neuromorphological deficits in a mouse model of D own syndrome
Corrales, A., Vidal, R., García-Cerro, S., Vidal, V., Martinez, P. M., García, E., Flórez, J., Sánchez‐Barceló, E. J., Martínez‐Cué, C., & Rueda, N. (2013) · Journal of Pineal Research · doi:10.1111/jpi.12097 · Cited by 53
Pathways to cognitive deficits in Down syndrome
Sturgeon, X., Le, T., Ahmed, M. M., & Gardiner, K. (2012) · Progress in brain research · doi:10.1016/b978-0-444-54299-1.00005-4 · Cited by 52
Early intervention with fluoxetine reverses abnormalities in the serotonergic system and behavior of rats exposed prenatally to dexamethasone
Nagano, M., Liu, M., Inagaki, H., Kawada, T., & Suzuki, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.03.027 · Cited by 51
Pharmacotherapy with Fluoxetine Restores Functional Connectivity from the Dentate Gyrus to Field CA3 in the Ts65Dn Mouse Model of Down Syndrome
Stagni, F., Magistretti, J., Guidi, S., Ciani, E., Mangano, C., Calzà, L., & Bartesaghi, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061689 · Cited by 53
Self-citation
Abnormal development of the inferior temporal region in fetuses with Down syndrome
Guidi, S., Giacomini, A., Stagni, F., Emili, M., Uguagliati, B., Bonasoni, M. P., & Bartesaghi, R. (2018) · Brain Pathology · doi:10.1111/bpa.12605 · Cited by 47
Self-citation
Abnormal MicroRNA Expression in Ts65Dn Hippocampus and Whole Blood: Contributions to Down Syndrome Phenotypes
Keck-Wherley, J., Grover, D., Bhattacharyya, S., Xu, X., Holman, D., Lombardini, E., Verma, R., Biswas, R., & Galdzicki, Z. (2011) · Developmental Neuroscience · doi:10.1159/000330884 · Cited by 48
Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome
Kleschevnikov, A. M., Yu, J., Kim, J., Lysenko, L. V., Zeng, Z., Yu, Y. E., & Mobley, W. C. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.009 · Cited by 49
Antidepressant Use and Cognitive Outcomes in Very Old Women
Leng, Y., Diem, S. J., Stone, K. L., & Yaffe, K. (2018) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glx226 · Cited by 48
On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome
Costa, A. C. S. (2011) · Developmental Neuroscience · doi:10.1159/000330861 · Cited by 44
Phf8 loss confers resistance to depression-like and anxiety-like behaviors in mice
Walsh, R. M., Shen, E., Bagot, R. C., Anselmo, A. N., Jiang, Y., Javidfar, B., Wojtkiewicz, G. R., Cloutier, J. K., Chen, J. W., Sadreyev, R. I., et al. (2017) · Nature Communications · doi:10.1038/ncomms15142 · Cited by 46
A randomized controlled trial of sertraline in young children with autism spectrum disorder
Potter, L. A., Scholze, D. A., Biag, H. M. B., Schneider, A., Chen, Y., Nguyen, D. V., Rajaratnam, A., Rivera, S. M., Dwyer, P. S., Tassone, F., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00810 · Cited by 43
From Basic Visual Science to Neurodevelopmental Disorders: The Voyage of Environmental Enrichment-Like Stimulation
Consorti, A., Sansevero, G., Torelli, C., Berardi, N., & Sale, A. (2019) · Neural Plasticity · doi:10.1155/2019/5653180 · Cited by 44
Sex differences in protein expression in the mouse brain and their perturbations in a model of down syndrome
Block, A., Ahmed, M. M., Dhanasekaran, A. R., Tong, S., & Gardiner, K. J. (2015) · Biology of Sex Differences · doi:10.1186/s13293-015-0043-9 · Cited by 43
Adult-Onset Fluoxetine Treatment Does Not Improve Behavioral Impairments and May Have Adverse Effects on the Ts65Dn Mouse Model of Down Syndrome
Heinen, M., Hettich, M. M., Ryan, D. P., Schnell, S., Paesler, K., & Ehninger, D. (2012) · Neural Plasticity · doi:10.1155/2012/467251 · Cited by 45
Stem and progenitor cell dysfunction in human trisomies
Liu, B., Filippi, S., Roy, A., & Roberts, I. A. G. (2014) · EMBO Reports · doi:10.15252/embr.201439583 · Cited by 44
Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome
Giacomini, A., Stagni, F., Trazzi, S., Guidi, S., Emili, M., Brigham, E. F., Ciani, E., & Bartesaghi, R. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.001 · Cited by 40
Self-citation
Serotonin dysregulation in Fragile X Syndrome: implications for treatment
Hanson, A. C., & Hagerman, R. J. (2014) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2014.01027 · Cited by 40
Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice
Mazur‐Kolecka, B., Golabek, A. A., Kida, E., Rabe, A., Hwang, Y., Adayev, T., Węgiel, J., Flory, M. J., Kaczmarski, W., Marchi, E. J., et al. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23007 · Cited by 44
APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome
Trazzi, S., Fuchs, C., Franceschi, M. D., Mitrugno, V. M., Bartesaghi, R., & Ciani, E. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.03.003 · Cited by 40
Self-citation
Signalling pathways contributing to learning and memory deficits in the Ts65Dn mouse model of Down syndrome
Freeburn, A., & Munn, R. G. K. (2021) · Neuronal Signaling · doi:10.1042/ns20200011 · Cited by 37
Molecular and genetic basis of depression
ROY, M., Tapadia, M. G., Joshi, S., & Koch, B. (2014) · Journal of Genetics · doi:10.1007/s12041-014-0449-x · Cited by 39
Review of targeted treatments in fragile X syndrome
Ligsay, A., & Hagerman, R. J. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01045 · Cited by 38
Both chronic treatments by epothilone D and fluoxetine increase the short‐term memory and differentially alter the mood status of STOP / MAP 6 KO mice
Fournet, V., de Lavilléon, G., Schweitzer, A., Bruno Giros, A., Andrieux, A., & Martres, M. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12027 · Cited by 37
Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors
Heller, H. C., Salehi, A., Chuluun, B., Das, D., Lin, B., Moghadam, S., Garner, C. C., & Colas, D. (2014) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2014.10.002 · Cited by 37
Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials
Rueda Revilla, N., & Martínez-Cué, C. (2020) · Antioxidants · doi:10.3390/antiox9080692 · Cited by 35
Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome
Navarro-Romero, A., Vázquez‐Oliver, A., Gomis‐González, M., Garzón-Montesinos, C., Falcón‐Moya, R., Pastor, A., Martín‐García, E., Pizarro, N., Busquets-García, A., Revest, J., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.01.014 · Cited by 39
Stress Responses in Down Syndrome Neurodegeneration: State of the Art and Therapeutic Molecules
Lanzillotta, C., & Domenico, F. D. (2021) · Biomolecules · doi:10.3390/biom11020266 · Cited by 36
Early environmental therapy rescues brain development in a mouse model of Down syndrome
Begenisic, T., Sansevero, G., Baroncelli, L., Cioni, G., & Sale, A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.07.014 · Cited by 35
Fluoxetine reverses brain radiation and temozolomide-induced anxiety and spatial learning and memory defect in mice
Gan, H., Zhang, Q., Zhu, B., Wu, S., & Chai, D. (2018) · Journal of Neurophysiology · doi:10.1152/jn.00581.2018 · Cited by 33
Synaptic Pathology of Down Syndrome
Garner, C. C., & Wetmore, D. Z. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-7091-0932-8_20 · Cited by 33
The Fetal Brain Transcriptome and Neonatal Behavioral Phenotype in the Ts1Cje Mouse Model of Down syndrome
Guedj, F., Pennings, J., Ferrés, M., Graham, L. C., Wick, H. C., Miczek, K. A., Slonim, D., & Bianchi, D. W. (2015) · American Journal of Medical Genetics. Part A · doi:10.1002/ajmg.a.37156 · Cited by 30
Antidepressants for neuro-regeneration: from depression to Alzheimer’s disease
Kim, H., Kim, W., & Kong, S.-Y. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0238-8 · Cited by 35
Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome
Powers, B. E., Velázquez, R., Kelley, C. M., Ash, J. A., Strawderman, M. S., Alldred, M. J., Ginsberg, S. D., Mufson, E. J., & Strupp, B. J. (2015) · Brain Structure and Function · doi:10.1007/s00429-015-1164-y · Cited by 34
New Perspectives for the Rescue of Cognitive Disability in Down Syndrome
Bartesaghi, R., Haydar, T. F., Delabar, J. M., Dierssen, M., Martínez‐Cué, C., & Bianchi, D. W. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.2775-15.2015 · Cited by 32
Self-citation
The in vivo Down syndrome genomic library in mouse
Hérault, Y., Duchon, A., Velot, É., Maréchal, D., & Brault, V. (2012) · Progress in brain research · doi:10.1016/b978-0-444-54299-1.00009-1 · Cited by 36
The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives
Stagni, F., & Bartesaghi, R. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.903729 · Cited by 33
Self-citation
Long-term running alleviates some behavioral and molecular abnormalities in Down syndrome mouse model Ts65Dn
Kida, E., Rabe, A., Walus, M., Albertini, G., & Golabek, A. A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.11.022 · Cited by 31
Molecular and Cellular Alterations in Down Syndrome: Toward the Identification of Targets for Therapeutics
Créau, N. (2012) · Neural Plasticity · doi:10.1155/2012/171639 · Cited by 30
Experience-dependent reduction of soluble β-amyloid oligomers and rescue of cognitive abilities in middle-age Ts65Dn mice, a model of Down syndrome
Sansevero, G., Begenisic, T., Mainardi, M., & Sale, A. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.06.006 · Cited by 31
Discoveries in Down syndrome
Kleschevnikov, A. M., Belichenko, P. V., Salehi, A., & Wu, C. (2012) · Progress in brain research · doi:10.1016/b978-0-444-54299-1.00010-8 · Cited by 30
Mouse models of cognitive disabilities in trisomy 21 (Down syndrome)
Roubertoux, P. L., & Carlier, M. (2010) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30280 · Cited by 28
Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome
Kazim, S. F., Blanchard, J., Bianchi, R., & Iqbal, K. (2017) · Scientific Reports · doi:10.1038/srep45561 · Cited by 28
Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues
London, J., Rouch, C., Bui, L. C., Assayag, E., Souchet, B., Daubigney, F., Medjaoui, H., Luquet, S. H., Magnan, C., Delabar, J. M., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0591-6 · Cited by 29
Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome
Ruparelia, A., Pearn, M. L., & Mobley, W. C. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2012.05.002 · Cited by 26
Neurotransmitter-based strategies for the treatment of cognitive dysfunction in Down syndrome
Das, D., Phillips, C., Hsieh, W., Sumanth, K., Dang, V., & Salehi, A. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.05.004 · Cited by 27
Chronic P7C3 treatment restores hippocampal neurogenesis
Latchney, S. E., Jaramillo, T. C., Rivera, P. D., Eisch, A. J., & Powell, C. M. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.02.008 · Cited by 26
Alterations of brain circuits in Down syndrome murine models
Gotti, S., Caricati, E., & Panzica, G. (2011) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2011.09.002 · Cited by 25
Brain circuit pathology in Down syndrome: from neurons to neural networks
Bartesaghi, R. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0067 · Cited by 25
Self-citation
Asynchronous excitatory neuron development in an isogenic cortical spheroid model of Down syndrome
Li, Z., Klein, J. A., Rampam, S., Kurzion, R., Campbell, N. B., Patel, Y., Haydar, T. F., & Zeldich, E. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.932384 · Cited by 24
Prenatal Administration of Oleic Acid or Linolenic Acid Reduces Neuromorphological and Cognitive Alterations in Ts65dn Down Syndrome Mice
García-Cerro, S., Rueda, N., Vidal, V., Puente, A., Campa, V. M., Lantigua, S., Narcís, J. O., Velasco, A. L., Bartesaghi, R., & Martínez‐Cué, C. (2020) · Journal of Nutrition · doi:10.1093/jn/nxaa074 · Cited by 23
Self-citation
Restoring microglial and astroglial homeostasis using DNA immunization in a down Syndrome mouse model.
Illouz, T., Madar, R., Biragyn, A., & Okun, E. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.10.004 · Cited by 22

Authors: Bianchi, P., Ciani, E., Guidi, S., Trazzi, S., Felice, D., Grossi, G., Fernandez, M., Giuliani, A., Calza, L., & Bartesaghi, R.
Affiliations: University of Bologna (IT)
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
Corresponding author: Bartesaghi, R.
ORCID: Ciani, E.
Guidi, S.
Trazzi, S.
Giuliani, A.
Bartesaghi, R.
Venue: Journal of Neuroscience
Publisher: Society for Neuroscience
Published: 2010-06-30
Volume: 30
Issue: 26
Pages: 8769-8779
ISSN: 0270-6474 (ISSN-L)
1529-2401
DOI: 10.1523/jneurosci.0534-10.2010
PMC: PMC6632890
OpenAlex: W2086398583
Cited by: 188
References: 62
Citations by year: 2026: 5 · 2025: 6 · 2024: 11 · 2023: 5 · 2022: 8 · 2021: 8 · 2020: 7 · 2019: 13 · 2018: 9 · 2017: 20 · 2016: 10 · 2015: 11 · 2014: 21 · 2013: 16 · 2012: 25
FWCI: 17.18
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Neuroscience (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords: Down syndrome, Ts65Dn mouse model, fluoxetine, neurogenesis, serotonin, 5-HT1A receptor, brain-derived neurotrophic factor, dentate gyrus, subventricular zone, striatum, neocortex, cell proliferation, contextual fear conditioning, hippocampal-dependent memory, intellectual disability
MeSH terms: Animals, Animals, Newborn, Brain, Cognition, Disease Models, Animal, Down Syndrome, Fluoxetine, Memory Disorders, Mice, Transgenic, Neurons, Serotonin, Stem Cells, Time Factors, Selective Serotonin Reuptake Inhibitors, Brain-Derived Neurotrophic Factor, Receptor, Serotonin, 5-HT1A, Cell Proliferation, Mice, Neurogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks